Health insurance premiums in the United States are projected to increase by nearly 9 percent in 2024, marking the largest hike in five years. This significant rise is primarily attributed to the growing use of weight loss medications, particularly GLP-1 drugs such as Ozempic. The increased costs are expected to impact millions of Americans, with estimates indicating that over 20 million people in the U.S. are currently using these medications.
According to a recent health tracking poll conducted by KFF, approximately 6 percent of the U.S. population is on GLP-1 treatment. Next year, those enrolled in the Affordable Care Act will face an alarming 75 percent increase in their health insurance costs. The surge in premiums is linked not only to the heightened demand for these weight loss drugs but also to tariffs on pharmaceutical imports implemented during the previous administration.
The use of GLP-1 medications has skyrocketed. As reported by Debbie Ashford, chief actuary at Aon, there was a staggering 92 percent increase in the utilization of these drugs in 2023, with another 56 percent rise expected in 2024. For some individuals, the cost of these medications can reach as high as $800 per month.
Insurance Implications and Employer Policies
Employers are responding to the rising costs associated with GLP-1 medications, as nearly 90 percent of companies require prior authorization for coverage. Many employers mandate that patients demonstrate significant overweight status, as determined by their body mass index, before receiving coverage for these drugs.
Furthermore, individuals traveling with GLP-1 medications must declare them on their travel insurance policies. Experts emphasize the importance of informing insurers about any prescribed medications. Failure to do so could result in the invalidation of a policy, even if the claim is unrelated to the treatment. Kara Gammell from the price comparison website Money Supermarket highlights that disclosing both the medication and underlying health issues is critical during the insurance process.
“Failing to do so could invalidate your cover – even if your claim has nothing to do with the treatment,” Gammell stated. She advises GLP-1 users to verify their insurance coverage before traveling to avoid potential complications.
As the popularity of GLP-1 medications continues to grow, the healthcare landscape is shifting significantly. The impending health insurance premium increases serve as a crucial reminder of the broader economic impacts of medical advancements and changing consumer behaviors. With over 24 million Americans relying on the Affordable Care Act, the ripple effects of these changes will be felt widely across the country.
